Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects

Pharmacodynamic models for “directly suppressive” effects of methylprednisolone are based on the premise that receptor interactions of steroids are followed by immediate suppression of either the circadian secretion of cortisol or the constant rate recirculation of histamine‐containing basophils that persists until inhibitory concentrations of methylprednisolone disappear. Methylprednisolone doses of 0, 10, 20, and 40 mg were given as the 21‐succinate sodium salt in a balanced crossover study to six normal men. Plasma steroid concentrations and blood histamine were measured simultaneously. Both forms of methylnisolone exhibited linear kinetic parameters. One dynamic model quantitates the baseline circadian pattern and the decline and return of cortisol with similar parameter estimates for all three dose levels. A similar model describes the monoexponential decline and the log‐linear return to steady‐state baseline of blood histamine. Similar inhibitory concentration values for both effects approximated the equilibrium dissociation constant of in vitro steroid receptor binding. The new models are more physiologically appropriate for these steroid effects than three other models that are commonly employed in pharmacodynamics. Steroid effects generally appear to be receptor mediated with either nongene immediate responses or gene‐mediated delayed effects. These models allow quantitation of the rapid effects of steroids with simple equations and common fitted parameters for all steroid dose levels.

[1]  R P STEPHENSON,et al.  A MODIFICATION OF RECEPTOR THEORY , 1997, British journal of pharmacology and chemotherapy.

[2]  N. Eberhardt,et al.  Glucocorticoid action: a mechanism involving nuclear and non‐nuclear pathways , 1982, The British journal of dermatology.

[3]  W J Jusko,et al.  LAGRAN program for area and moments in pharmacokinetic analysis. , 1983, Computer programs in biomedicine.

[4]  M. Dallman,et al.  Corticosteroid inhibition of ACTH secretion. , 1984, Endocrine reviews.

[5]  W J Jusko,et al.  Partial pharmacodynamic model for the circadian-episodic secretion of cortisol in man. , 1975, The Journal of clinical endocrinology and metabolism.

[6]  A. Fauci,et al.  Corticosteroid‐Mediated Immunoregulation in Man , 1982, Immunological reviews.

[7]  F. Frey,et al.  Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function. , 1984, Journal of immunology.

[8]  W. Jusko,et al.  Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion , 1986, Clinical pharmacology and therapeutics.

[9]  E. Leonard Two populations of human blood basophils: effect of prednisone on circulating numbers. , 1987, The Journal of allergy and clinical immunology.

[10]  L. Lichtenstein,et al.  Inhibition of basophil histamine release by anti-inflammatory steroids. II. Studies on the mechanism of action. , 1982, Journal of immunology.

[11]  C. George Drug Kinetics and Hepatic Blood Flow , 1979, Clinical pharmacokinetics.

[12]  W. Jusko,et al.  Simultaneous analysis of methylprednisolone hemisuccinate, cortisol and methylprednisolone by normal-phase high-performance liquid chromatography in human plasma. , 1988, Journal of chromatography.

[13]  D. Krieger Circadian pituitary adrenal rhythms. , 1975, Advances in experimental medicine and biology.

[14]  G. Asnis,et al.  Cortisol secretion in endogenous depression. II. Time-related functions. , 1985, Archives of general psychiatry.

[15]  K. Hattori,et al.  Characterization of steroid hormone ester hydrolyzing enzymes in liver microsomes. , 1981, Biochemical pharmacology.

[16]  R. Gabbard Receptors and mechanism of action of steroid hormones , 1977, Steroids.

[17]  G. Rousseau Control of gene expression by glucocorticoid hormones. , 1984, The Biochemical journal.

[18]  R. Levy,et al.  Prediction of steady-state behavior of metabolite from dosing of parent drug. , 1980, Journal of pharmaceutical sciences.

[19]  L B Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. , 1980, Clinical pharmacology and therapeutics.

[20]  M. Dallman,et al.  Corticosteroid Feedback Control of Stress-Induced ACTH Secretion1 , 1973 .

[21]  K. Fuxe,et al.  Biochemistry, molecular biology, and physiology of the glucocorticoid receptor. , 1987, Endocrine reviews.

[22]  S. Spector,et al.  The effect of troleandomycin on methylprednisolone elimination. , 1980, The Journal of allergy and clinical immunology.

[23]  R. Engler,et al.  The effects of triacetyloleandomycin and oleandomycin phosphate on the glucocorticoid receptor in cultured skin fibroblasts. , 1985, The Journal of allergy and clinical immunology.

[24]  W. Jusko,et al.  Analysis of cortisol, methylprednisolone, and methylprednisolone hemisuccinate. Absence of effects of troleandomycin on ester hydrolysis. , 1984, Journal of chromatography.

[25]  David G. Covell,et al.  Systems and Microcomputer Approach to Anticoagulant Therapy , 1980, IEEE Transactions on Biomedical Engineering.

[26]  P. L. Ballard Delivery and transport of glucocorticoids to target cells. , 1979, Monographs on endocrinology.

[27]  G Levy,et al.  Kinetics of pharmacologic effects , 1966, Clinical pharmacology and therapeutics.

[28]  W. Jusko,et al.  6α‐methylprednisolone and 6α‐methylprednisone plasma protein binding in humans and rabbits , 1986 .

[29]  F. H. Tyler,et al.  Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. , 1977, The American journal of medicine.

[30]  H. Möllmann,et al.  Kinetics of methylprednisolone and its hemisuccinate ester , 1985, Clinical pharmacology and therapeutics.

[31]  A. Fauci,et al.  The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. , 1974, The Journal of clinical investigation.

[32]  Glucocorticoids selectively inhibit the transcription of the interleukin 1 beta gene and decrease the stability of interleukin 1 beta mRNA. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[33]  H. Davson Blood–brain barrier , 1977, Nature.

[34]  J. Eberwine,et al.  Complex transcriptional regulation by glucocorticoids and corticotropin-releasing hormone of proopiomelanocortin gene expression in rat pituitary cultures. , 1987, DNA.

[35]  H. Rogers,et al.  Methylprednisolone pharmacokinetics after intravenous and oral administration. , 1989, British journal of clinical pharmacology.

[36]  G. Levy,et al.  Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin , 1969, Clinical pharmacology and therapeutics.

[37]  E. Fischler,et al.  Early effects of corticosteroids on basophils, leukocyte histamine, and tissue histamine. , 1979, The Journal of allergy and clinical immunology.

[38]  W. Heubner,et al.  Handbuch der Experimentellen Pharmakologie: Ergänzungswerk , 1937 .

[39]  J. Buckingham The influence of corticosteroids on the secretion of corticotrophin and its hypothalamic releasing hormone , 1979, The Journal of physiology.

[40]  F Halberg,et al.  Methods for cosinor-rhythmometry. , 1979, Chronobiologia.